TP53 and neoplasm: In contrast, the same therapy demonstrated a downward trend in tumor growth for HCT-116 p53+/+ xenografts, though this difference was not significant by the time mice were required to be sacrificed due to institutional policy and ethical concerns (Figure 1B, second graph blue line).